Key facts
- It has raised $27.6M; the latest was Later Stage VC ($8.3M) in May 2025.
- Notable investors include Stockholm Innovation & Growth, Energimyndigheten, Flerie, Horizon 2020, Lareim — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for SymCel
- ·The full record, as it builds
Funding rounds
No funding rounds for SymCel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SymCel
Manufacturer of scientific instruments with accompanying consumables designed to conduct research and development in the field of biotechnology. The company's tools serve as a label-free assay technology that provides real-time, continuous monitoring of cell metabolism, biological activity, and heat produced by living cells during metabolism, enabling researchers and clinicians to detect previously unknown stories and generate novel insights and data with speed and accuracy.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2004
- Employees
- 57
- Website
- symcel.com/
- Ownership
- Privately Held (backing)
SymCel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SymCel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SymCel in its N-PORT filings yet. We sweep new filings monthly.